JamesJ DHsiehMD

PubMed

• 1 citations
  Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNO...
  Chung-Han Lee, Amishi Yogesh Shah, Arpit Rao, Matthew H Taylor, Christopher Di Simone
  European Urology. 2024-11-01
• 1 citations
  Author Correction: Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma.
  Yige Wu, Nadezhda V Terekhanova, Wagma Caravan, Nataly Naser Al Deen, Preet Lal
  Nature Communications. 2023-05-17
• 16 citations
  Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma.
  Yige Wu, Nadezhda V Terekhanova, Wagma Caravan, Nataly Naser Al Deen, Preet Lal
  Nature Communications. 2023-03-27

Journal Articles

• Hyperpolarized MRI Visualizes Warburg Effects and Predicts Treatment Response to mTOR Inhibitors in Patient-Derived ccRCC Xenograft Models  
  James Hsieh, MD, Clinical Cancer Research
• Analysis of Renal Cancer Cell Lines from Two Major Resources Enables Genomics-Guided Cell Line Selection  
  Satish K Tickoo, Paul Russo, A Ari Hakimi, Victor E Reuter, James J Hsieh, Jonathan A Coleman, Michael Chevinsky, Christopher Jakubowski, Andrew G Winer, Nature
• Efficacy Genomic Biomarkers of a Randomized Trial Comparing First-Line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma  
  Hsieh JJ, David Chen, Patricia I. Wang, Mahtab Marker, Almedina Redzematovic, Ying-Bei Chen, S. Duygu Selcuklu, Nils Weinhold, Nancy Bouvier, Kety H. Huberman, Umesh B..., Eur Urol, 1/14/2016
• Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components  
  Manley BJ, Hsieh JJ, Transl Caner Res, 1/1/2016
• Integration of recurrent somatic mutations with clinical outcomes: a pooled analysis of 1049 clear cell renal cell carcinoma patients  
  Manley BJ, Zabor EC, Casuscelli J, Tennenbaum DM, Redzematovic A, Becerra MF, Benfante N, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Ogawa S, Arcila ME, Voss MH,..., Eur Urol Focus, 1/1/2016
• Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma but not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Sam...  
  Dong Y, Manley BJ, Becerra MF, Redzematovid A, Casuscelli J, Tennebaum DM, Reznik E, Han S, Benfante N, Chen Y, Arcia ME, Aras O, Voss MH, Feldman DR, Motzer RJ, Fabbr..., Eur Urol Focus, 1/1/2016
• Modeling Tumor Growth for Kidney Cancer Based on Nuclei Clusters of Pathology Slides  
  Saribudak A, Dong Y, Hsieh JJ, Uyar MU, Inter J Engineering and Technology, 1/1/2016
• Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant mRNA signatures  
  Senbabaoglu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley B, Khalil DN, Kaffenberger SD, ..., Genome Biology, 1/1/2016
• The Panoramic View of Clear Cell Renal Cell Carcinoma Metabolism: Values of Integrated Global Cancer Metabolomics  
  Hsieh JJ, Cheng EH, Trans Andro Urol, 1/1/2016
• A braided cancer river connects tumor heterogeneity and precision medicine  
  Hsieh JJ, Cheng EH, Clinical and Translational Medicine, 1/1/2016
• Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets associated with varying clinical outcomes  
  Chen Y, Xu J, Skanderup, AJ, Dong Y, Brannon AR, Wang L, Won WH, Wang PI, Nanjangud GJ, Jungbluth AA, Li W, Ojeda V, Hakimi AA, Voss MH, Schultz N, Motzer RJ, Russo P,..., Nat Comm, 1/1/2016
• ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma  
  Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell WK, Eur Urol, 1/25/2014
• A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma  
  Funakoshi T, Lee CH, Hsieh JJ, Cancer Treat Rev, 1/1/2014
• Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy  
  Voss MH, Hakimi AA, Pham CG, Brannon AR, Chen YB, Cunha LF, Akin O, Liu H, Takeda S, Scott SN, Socci ND, Viale A, Schultz N, Sander C, Reuter VE, Russo P, Cheng EH, Mo..., Clin Cancer Res, 1/1/2014
• Radiogenomics of clear-cell renal cell carcinoma: Associations between CT imaging features and mutations  
  Karlo CA, Di Paolo PL, Chaim J, Hakimi AA, Ostrovnaya I, Russo P, Motzer RJ, Hricak H, Tickoo SK, Reuter VE, Hsieh JJ, Akin O, Radiology, 1/12/2013
• Clear Picture of Renal Cell Carcinoma  
  Hakimi AA, Pham CG, Hsieh JJ, Nature Genetics, 1/1/2013
• Comprehensive Molecular Characterization of clear cell renal cell carcinoma  
  The Cancer Genome Atlas Research Network* (Hsieh JJ), Nature, 1/1/2013
• An Epidemiologic and Genomic Investigation into the Obesity Paradox in Clear Cell Renal Cell Carcinoma  
  Hakimi AA, Furberg H, Zabor EC, Jacobsen A, Schultz N, Ciriello G, Mikklineni N, Fiegoli B, Kim PH, Voss MH, Shen H, Laird PW, Sander C, Reuter VE, Motzer RJ, Hsieh JJ..., JNCI, 1/1/2013
• Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: a Report by MSKCC and the KIRC TCGA Research Network  
  Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen Y, Gonen M, Liu H, Takeda S, Voss MH, Tickoo SK, Reuter VE, Russo P, Cheng EH, Sander C, Motzer RJ, Hsieh JJ for The c..., Clin Can Res, 1/1/2013
• Clinical and Pathologic Impact of Select Chromatin Modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma  
  Hakimi A, Chen Y, Wren J, Gonen M, Abdel-Wahab O, Heguy A, Liu H, Takeda S, Tickoo SK, Reuter VE, Voss MH, Motzer RJ, Coleman JA, Cheng EH, Russo P, Hsieh JJ, Eur Urol, 1/27/2012
• Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer  
  Vanharanta S, Shu W, Brenet F, Hakimi AA, Heguy A, Viale A, Reuter VE, Hsieh JJ, Scandura JM, Massague J, Nat Med, 1/9/2012
• A Pharmacologic Inhibitor of the Protease Taspase1 Effectively Inhibits Breast and Brain Tumor Growth  
  Chen DY, Lee Y, Van Tine BA, Searleman AC, Westergard TD, Liu H, Tu HC, Takeda S, Dong Y, Piwnica-Worms DR, Oh KJ, Korsmeyer SJ, Hermone A, Gussio R, Shoemaker RH, Che..., Cancer Research, 1/1/2012
• Phosphorylation of MLL by ATR is Required for Execution of Mammalian S Phase Checkpoint  
  Liu H., Takeda S., Kumar R., Westergard T.D., Brown E.J., Pandita T., Cheng E.H.-Y., Hsieh JJ, Nature, 1/1/2010
• Taspase1 Functions as a Non-oncogene Addiction Protease that Coordinates Cancer Cell Proliferation and Apoptosis  
  Chen D.Y., Liu H., Takeda S., Tu H., Sasagawa S, Van Tine B., Lu D., Cheng E.H.-Y., Hsieh JJ, Cancer Research, 1/1/2010
• The VDAC2-BAK Rheostat Controls Thymocyte Survival  
  Ren D., Kim H., Tu H., Westergard T.D., Fisher J.K., Rubens J.A., Korsmeyer S.J., Hsieh JJ, Cheng E.H.-Y., Science Signaling, 1/1/2009
• Join now to see all

Books/Book Chapters

• Renal Cell Carcinoma: Molecular Targets and Clinical Applications 
  Chapter: PBRM1: A Critical Subunit of the SWI/SNF Chromatin Redmodeling Complex. 
  Lee CH, Pham CG, Hsieh JJEdition 3rd,2015
• Handbook of Proteolytic Enzymes. 
  Chapter: Taspase1. 
  Cunha L, Tong L, Hsieh JJEditors: Neil D. Rawlings, Guy Salvesen.2013